论文部分内容阅读
醋酸甲羟孕酮针剂(DMPA)为每3个月肌肉注射1次的长效避孕针,于1992年获美国食品和药物管理局(FDA)正式批准作为避孕药使用。目前全世界90多个国家900多万妇女接受此法避孕。由印尼三金龙药厂生产的醋酸甲羟孕酮避孕针(商品名迪波盖斯通)于1994年10月在中国注册。湖北省在1995年10月～1997年2月作为分中心之一参加全国引入性试验的部分工作,现将临床应用情况总结如下。
Medroxyprogesterone acetate injection (DMPA) is a long-acting injectable intramuscular injection once every 3 months and was officially approved as a contraceptive by the U.S. Food and Drug Administration (FDA) in 1992. At present, more than 9 million women in over 90 countries around the world receive this method of contraception. Medroxyprogesterone acetate contraceptive (trade name Dubois Gaston), manufactured by Indonesia’s Samuelong Pharmaceuticals, was registered in China in October 1994. Hubei Province from October 1995 to February 1997 as part of one of the sub-centers to participate in the national part of the pilot project, the clinical application is summarized as follows.